unknown by unknown
0.33M (+/-0.13M) in a cell-free assay
1.  RHPS4 is a novel pentacyclic 
acridine (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium 
methosulphate) synthesised at Nottingham.   
The aims of the study were to investigate the pharmaceutical and biological 
properties of RHPS4 to assess whether it was a suitable drug for further 
development and to validate telomerase inhibitory effects by RHPS4 at the 
pre-clinical, in vitro stage.  RHPS4 has been shown to possess convenient 
pharmaceutical properties: high aqueous solubility (>5mg/ml) was 
determined by UV absorbance and its stability under tissue culture conditions 
confirmed by HPLC assay.  Fluorescence activated cell sorting has shown 
rapid cell uptake of the drug in the breast and lung cancer cell lines MCF-7 
and A549 respectively.  Saturation of drug uptake is approached after 
approximately six hours (MCF-7 cells) or two hours (A549 cells) at 37C; 
uptake is much slower at 4
oC .   N a t u r a l l y  f l u o r e s c e n t ,  R H P S 4  c a n  b e  
visualised in the nuclei of these cells within 30 minutes by fluorescence 
confocal microscopy.   
Concentrations causing low acute cytotoxicity (1M as determined by 
four-day MTT assays) have been used in the study of the biological effects of 
the drug to avoid toxic effects not attributable to telomerase inhibition. In 
longer-term studies of cell viability, concentrations 1M cause the 
proportion of dividing cells to decrease with time of treatment.  Further, 
RHPS4 induces a senescent phenotype in a proportion of the cell population 
beginning after 8 days in culture.  The proportion of senescent cells increases 
with time of treatment consistent with the expected effects of telomerase 
inhibition.  In contrast, apoptosis appears not to be a predominant feature of 
the drug’s mechanism of action, as determined by cell cycle analysis 
(absence of a pre-G1 peak).  In conclusion, RHPS4 represents a promising 
small molecule inhibitor of this important anticancer target.   
1 Gowan SM et al Mol Pharmacol 2001 60: 981-988 
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EFFECTS OF FLAVOPIRIDOL AND 5-FLOROURACIL ON MCF-7 
HUMAN BREAST CANCER CELLS 
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Institute for Cancer Studies and Institute of Endocrinology, Division of 
Genomic Medicine, Sheffield University, Medical School, Sheffield, UK 
 
Flavopiridol (FP) is a novel cyclin-dependent kinase (CDKs) inhibitor.  It is 
currently under phase II clinical trial.  Several studies have shown that FP 
inhibits the growth of many human tumour cells and also causes an early 
specific decline in cyclin D1 in MCF-7 human breast cancer cells (1).  In this 
work, our aim was to evaluate the effects of FP in combination with currently 
used drug 5-Fluorouracil (5-FU) on MCF-7 cell line.  We have treated MCF-
7 breast cancer cells with FP and 5-FU individually and in combination using 
different concentrations. 
The apoptotic effects of FP and 5-FU were measured using different methods 
including, In situ nick translation assay and Annexin V assay.  In addition, 
the apoptotic nuclei were clearly visualised on fluorescent microscope using 
4,6-diamidino-2-phenylindole (DAPI) stain.  Results of In situ nick 
translation and Annexin V assays were obtained by flow cytometry.  Cells 
were counted using a coulter counter and the effects of both drugs monitored 
every half-hour by time lapse microscopy. 
The maximum growth inhibition achieved after 48 hours when 5-FU 
(0.01M) was given two hours after FP (0.1M) was 61%, where as FP 
(0.1M) and 5-FU (0.01M) individually caused 50% and 39% growth 
inhibition respectively.  However, the effect of this combination was not 
much different (63%) when 5-FU was given 24 hours after FP.  
After treatment of the cells with the same drug combination, 45% of the cells 
undergo apoptosis.  Interestingly, only 9% of the cells were apoptotic after 
treatment of the cells with a much higher concentration of FP alone (0.5M), 
more cells undergo late apoptosis as shown by Annexin V assay.  Similarly, 
5-FU alone at concentration of (1M) leads to apoptosis in only 11% of the 
cells. 
In summary, these results showed that the effects of FP and 5-FU on MCF-7 
breast cancer cells using these combinations did not give any sigh of 
synergism, unlike the lung cancer cell line A549 (2).  In addition, the killing 
mechanisms in both of the drugs might not be completely apoptotic. 
                                                           
 
1-Carlson et al, 1999.  Cancer Research 59: 4634. 
2-Bible & Kaufmann, 1997.  Cancer Research 57: 3375. 
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Introduction: Von Hippel-Lindau (VHL) syndrome is a rare autosomal 
dominant familial cancer syndrome caused by germline mutations in the 
VHL tumour suppressor gene causing transcriptional activation of vascular 
endothelial growth factor(VEGF)gene and aberrant angiogenesis, leading to 
early onset retinal angiomas, cerebellar and spinal haemangioblastomas, renal 
cysts, and risks of renal cancer and other solid tumours. Retinal blindness, 
severe neurological morbidity, and the need for bilateral nephrectomy and 
transplantation are the difficult issues in the management of these patients. 
Patients with VHL are candidates for a chronic anti -angiogenic treatment 
strategy. Feasibility of such a therapy and the long-term toxicity of anti-
angiogenic drugs currently under evaluation in solid tumours is largely 
unknown and VHL patients could provide valuable information for future 
cancer trials. We initiated a phase I/II trial of chronic therapy with SU 5416, 
a tyrosine kinase inhibitor and a potent inhibitor of VEGF mediated Flk-1 
signaling, in VHL patients. Objectives and methods: The primary objectives 
of the study were to assess safety, tolerability, response rates, serial changes 
in disease activity and surrogate markers of angiogenesis inhibition following 
chronic therapy with SU5416. Patients with proven VHL syndrome were 
eligible for the study if they had symptomatic VHL not amenable to standard 
therapy, or multiple renal lesions likely to lead to transplantation or 
progressive disease, with good performance status, adequate renal, hepatic 
and bone marrow profiles. Patients received SU5416 at a dose of 145 mg/m
2 
given intravenously (initial cohort of 2 patients received once weekly and the 
rest twice weekly). Each cycle consisted of 4 weeks of treatment. Toxicity 
and disease evaluation was done 4 and 12 weekly respectively. Biological 
marker analysis was done pre-treatment, weeks 4, 8 and 12. Results: A total 
of 6 patients were entered into the study (3M and 3F) with a median age of 
34.5 years (range 26-42). Prior to entry into the study, 6 patients had 
neurosurgery and 2 patients retinal laser therapy. All patients had retinal 
angiomas,and/or CNS haemangioblastomas and/or renal cysts. A total of 51 
cycles of therapy was administered with an average of 8.5 cycles per patient 
(range 1.5-22.4 cycles).  Three patients achieved stabilization of disease 
whilst on therapy lasting for 20.6, 16.3 and 5.5 months respectively. There 
was  <50% reduction of a lumbar spinal lesion. There was complete 
regression of retinal lesion in one patient. The treatment was not as well 
tolerated as in cancer, with 1 patient discontinuing for pruritus and another 
having 50% dose reduction for pruritus. Conclusions: SU5416 was well 
tolerated. Chronic anti- antiangiogenic therapy is feasible and safe in this 
small group of patients. Regression of retinal lesion was seen in one patient 
though no PR/CR were seen. Future studies will be important with chronic 
oral therapy initiated early, since the late stages here had scarring and 
secondary problems that may not be blocked by VEGF antagonism . 
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vascular endothelial growth factor(VEGF) in the growth and metastasis of 
melanoma and this correlates with a poor prognosis. Suppression of VEGF 
causes tumour regression in animal models. SU5416 is a tyrosine kinase 
inhibitor and a potent inhibitor of VEGF mediated Flk-1 signalling. 
Pharmacokinetic and toxicity data is available from several phase I studies. 
An international phase II study was initiated to investigate the role of 
SU5416 in locally advanced or metastatic melanoma. Objectives and 
methods: The primary objectives of the study  were to assess tumour 
response, duration of response and progression free survival. Analysis of 
possible biological markers of angiogenesis inhibition and assessment of 
toxicity were the secondary objectives. Inclusion criteria included 
histologically proven progressive stage III or IV melanoma not amenable to 
standard therapy, ECOG performance status 0-2, adequate renal, hepaticand 
bone marrow  profiles. Eligible patients received SU5416 at a dose of 145 
mg/m
2 given as an intravenous infusion on days 1 and 4 of every week. Each 
cycle consisted of 4 weeks of treatment with responding patients continuing 
treatment for upto 1 year. Disease evaluation was performed after four and 
eight weeks of treatment and two monthly thereafter. Toxicity assessment 
was done at two weekly intervals. Blood samples for assessment of biological 
markers were collected  on days 1, 4, 8, 22 and 4 weekly from then on. 
Results: A total of twenty patients were entered into the study( 10 males and 
10 females) with a median age of 53.5 years (range 23-71). ECOG 
performance status of 0 (four patients) and 1(sixteen patients). Prior to entry 
into the study,  eighteen patients had received surgery, eighteen patients had 
systemic therapy [ immunotherapy (INF- alpha, IL-2 and others) and/or 
chemotherapy ( DTIC and others) and/or tamoxifen] and five patients had 
radiotherapy. A total of 42 cycles of therapy was administered with an 
average of 2.05 cycles per patient. Sixteen patients were evaluable for disease 
response. Six patients (37.5%) had stable disease whilst on therapy lasting 
less than three months and all others had progressive disease. Median time to 
progression was 41 days. Treatment was well tolerated with asthenia, 
headache, nausea, vomiting and anorexia as common side effects. Analysis of 
surrogate markers of angiogenesis inhibition is pending at this 
time.Conclusions:  SU5416 was well tolerated and side effects were as 
expected from previous studies. Single agent SU5416 seems ineffective in 
this group of heavily pre treated patients with a high tumour burden. Future 
studies in combination with immunotherapy or chemotherapy or blockers of 
other angiogenic pathways are likely to be more promising. 
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The prognosis for patients with metastatic melanoma is poor. Palliative 
chemotherapy does not significantly improve survival and new approaches to 
therapy are urgently required. Evidence suggests that melanoma can 
stimulate specific humoral (resulting in antibody production) and cellular (via 
stimulation of cytotoxic T cells [CTLs] by antigen on the surface of antigen 
presenting cells [APC]) immune responses. Peptide epitopes derived from 
melanoma-associated antigens are targets for CTLs in the context of HLA-
A2. Immunisation of patients with melanoma using these peptide epitopes 
may elicit an adequate immune response resulting in lysis of tumour cells. 
Immune adjuvants such as granulocyte-macrophage colony stimulating factor 
(GM-CSF) may augment this immune response. 
AIM: The primary objectives were to i) determine immunological response 
as determined by delayed tissue hypersensitivity (DTH) reactions at the site 
of injections and induction of CTLs as measured by a chromium release 
assay, and ii) to define the safety and toxicity profile of vaccination. Clinical 
response was documented as a secondary endpoint.  
METHODS: After obtaining informed consent, eligible patients were 
vaccinated with 100micrograms of each of 3 synthetic peptides – tyrosinase, 
gp-100 and melan-A (intradermal) with GM-CSF adjuvant (intramuscular) 
weekly for 4 weeks followed by a 4 week break (1 cycle) for up to 3 cycles. 
DTH reactions were assessed at 48h after the first vaccination of each cycle. 
Venous samples for CTL assays were obtained at intervals pre- and post- 
each vaccination cycle. Tumour responses were assessed clinically and 
radiologically after each 8-week cycle. Approval for the study was obtained 
from the local ethics committee. 
RESULTS: An initial 9 patients with a median age of 54 were recruited. Four 
patients had soft tissue and/or nodal metastases, 2 had lung metastases and 3 
had liver metastases. Two patients demonstrated DTH reactions to gp100 and 
melan-A respectively with associated CTL reactivity against target cells 
pulsed with the relevant peptide. Both of these patients (one with soft tissue 
disease, the other with lung metastases) had stable disease after 3 and 2 
cycles of treatment respectively. Vaccination was associated with mild 
transient pain at the sites of injection; GM-CSF injection resulted in grade 1 
local reaction in 4 patients. 
CONCLUSION: Vaccination using melanoma-associated peptides with GM-
CSF adjuvant is well tolerated and capable of eliciting immune responses that 
may be associated with clinical responses in selected patients with metastatic 
melanoma.  
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Amidox (3,4-dihydroxybenzamidoxime), a new polyhydroxy-substituted 
benzoic acid derivative, is a potent inhibitor of the enzyme ribonucleotide 
reductase, which catalyses the de novo synthesis of DNA. It is considered to 
be an excellent target for anti cancer chemotherapy, as its activity is 
significantly increased in malignant tumor cells. In our study we investigated 
the biochemical and antineoplastic effects of amidox. First, we incubated HL-
60 human promyelocytic leukemia cells with various concentrations of 
amidox for 48 and 96 hours. Amidox inhibited the growth of HL-60 cells in a 
growth inhibition assay with an IC50 of 30 µM. In a soft agar colony forming 
assay, amidox yielded a 50% inhibition of colony formation at 20 µM. In 
addition we investigated the effects of amidox treatment on the formation of 
deoxynucleosidetriphosphates, which are the precursors of DNA. Amidox 
(75 and 100 µM for 24 hours) could significantly decrease dCTP, dGTP and 
dTTP pools and caused an increase of the intracellular dATP concentration. 
We also tested the combination effects of amidox with Ara-C, a widely used 
compound for the treatment of leukemia. This combination yielded additive 
cytotoxic effects both in growth inhibition and soft agar colony formation 
assays. This effect was due to the increased formation of Ara-CTP, the active 
metabolite of Ara-C after preincubation with amidox. This was shown by 
measuring the intacellular Ara-CTP concentrations using HPLC. 
Preincubation of HL-60 cells with 75 and 100 µM amidox for 24 hours 
caused an increase in the intracellular Ara-CTP concentrations by 576% and 
1143%, respectively. We conclude that amidox is capable to inhibit the 
growth and colony formation of HL-60 cells at concentrations which can be 
achieved in vivo.The compound decreases dNTP pools and caused a 
concomitant increase of Ara-CTP. Therefore this compound might be further 
investigated in in vivo studies for the treatment of leukemia. 
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Programmed cell death (Apoptosis) is a common biochemical process 
underlying the pharmacodynamics of cytotoxic chemotherapy. Intrinsic 
neoplastic cellular resistance to apoptosis remains a major obstacle limiting 
efficacy. Multidomain death agonist proteins of the Bcl-2 family Bax and 
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by chemotherapy, and target mitochondria. Bcl-2 and its multidomain 
homologue Bcl-XL, widely expressed in several malignancies, heterodimerize 
to death agonists Bax and Bak, inhibiting their proapoptotic action on 
mitochondria. We have investigated the relative proapoptotic activity of three 
recently discovered, structurally unrelated, small molecule Bcl-2 antagonists, 
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxyethyl)-4H-chromene-3-
carboxylate (HA14-1), 2’ methoxy-antimycin A3 (2MAMA3), and 5-
benzylidine-a-isopropyl-4-oxo-2-thioxo-3-thiozolidinacetic acid (BH3I-1). 
These Bak peptide mimetics (BBPMs) bind  Bcl-2 with micromolar affinity, 
preventing Bax-Bak heterodimerization, and induce apoptosis. BBPM 
induced dissipation of FCCP sensitive mitochondrial membrane potential was 
measured at single cell resolution in RAMOS Burkitt lymphoma cells using 
an amphipathic fluorophore DiOC6(3) and propidium iodide. Cumulative 
frequency distributions (CDFs) of tolerance measured at 24, 48, and 72 
hours, were modelled by non-linear regression using the maximum likelihood 
method. A corresponding rank order of median tolerance was determined 
with maximum likeihood error estimates as HA14-1 > 2MAMA3 > BH3i-1. 
This rank order exhibited strong positive correlation (Pearson’s r > 0.95) with 
published Bak peptide-Bcl-2/Bcl-XL binding affinities. Apoptosis measured 
by changes in morphology, Z-DEVD.fmk inhibitable outer plasma membrane 
phospholipid unpacking (using MC540), and caspase 3 activation, 
accompanied mitochondrial depolarization. Ramos cells transfected with full 
length Bcl-2 cDNA (Ramos/Bcl-2), exhibited significant tolerance to  VP16, 
reactive oxygen species (H202, and tert- butylhydroperoxide), and VP16 
compared to vector only transfected control cells. Furthermore, Bcl-2 
transfection shifted the CDF of tolerance to mitochondrial depolarization to 
the right, for all the BPPMs studied. Potency ratios of median tolerance for 
Bcl-2 transfected versus vector only transfected lymphoma cells, were of low 
magnitude; HA14-1 (2.5), 2MAMA3 (1.6), BH3I-1 (2).  In summary, this 
study has quantitatively compared for the first time, the proapoptotic activity 
and Bcl-2 sensitivity of first generation small molecule Bcl-2/Bcl-XL 
antagonists. Studies to investigate interactions with chemotherapy, and pro-
apoptotic pharmcodynamics, are in progress. Such pharmacophores could 
provide novel leads for therapeutically reversing of Bcl-2 mediated 
chemoresistance in cancer.  
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The novel antitumour agent, 2-(4-amino-3-methylphenyl)-5-
fluorobenzothiazole (5F 203) elicits potent and selective anticancer activity in 
vitro and in vivo. The growth of MCF-7 and IGROV-1 cells is inhibited (GI50 
< 10 nM) whereas MDA-MB-435 cells are inherently resistant (GI50 > 100 
M). When MCF-7 and MDA-MB-435 xenografts are transplanted s.c. in 
opposite flanks of the same mouse, the growth of MCF-7 tumours only is 
significantly inhibited by 5F 203. The dihydrochloride salt of lysyl amide 
prodrug of 5F 203 (Phortress) has been formed through conjugation with the 
exocyclic primary amine function. In vivo, Phortress significantly inhibits the 
growth of IGROV-1 and MCF-7 tumours. Its unique mechanism of action 
includes bioreversion to parent amine in the presence of tumour cells, ligand 
binding to cytosolic aryl hydrocarbon receptor (AhR) in sensitive cells, 
receptor translocation, formation of protein complexes on the CYP1A1 
promoter, induction of CYP1A1 mRNA, activity and protein expression with 
NADPH-dependent covalent binding to CYP1A1. Subsequent formation of 
reactive electrophilic species lead to generation of lethal Phortress-derived 
DNA adducts. Putative pharmacodynamic (PD) endpoints undergoing 
preclinical evaluation include examination of AhR translocation, CYP1A1 
protein expression, PET studies and formation of DNA adducts in tumour 
cells and tissue following treatment with Phortress. In vitro, 1M Phortress 
generated 1 major and a number of minor adducts in MCF-7 and IGROV-1 
cells.  These adducts were chromatographically identical to those generated 
in DNA of MCF-7 cells following exposure to 5F 203. In vivo, Phortress-
derived DNA adducts were detected in MCF-7 and IGROV-1 xenografts. 
Striking selective formation of DNA adducts in MCF-7 xenografts tissue 
only, distinguished sensitive (MCF-7) tumours from insensitive (MDA-MB-
435) tumours transplanted in opposite flanks of the same animal. Comet 
assays, alkaline elution and fluorescence analyses of DNA unwinding 
(FADU) have confirmed massive DNA damage in sensitive (e.g. MCF-7) 
cells following treatment with 5F 203. Our studies are consistent with the 
hypothesis that this class of agent ultimately exerts its biological activity 
through covalent binding with DNA. The techniques studied offer potential 
for evaluation of a PD endpoint which may be predictive of tumour 
sensitivity of Phortress. Phase I clinical trials of Phortress are scheduled to 
begin in autumn 2002, under the auspices of CRUK. 
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Background: Malignant carcinoid tumors are rare and often associated with 
a specific syndrome, more than 70% are functional. Hormones and proteins 
that are released and associated with the syndrome are co-stored and co-
released with Chromogranin A (CgA).  CgA has been shown to be a sensitive 
and specific marker for carcinoid tumors, regardless of the tumors’ functional 
status. The mechanism of release from the tumors may be partly exocytotic, 
and a positive biological gradient appears to reflect an increasing tumor load 
and therefore may be an independent marker of prognosis. Carcinoid tumors 
express a variety of receptors for somatostatin (SSTR), of which there are 
five known subtypes. The somatostatin analog, octreotide, binds with a high 
affinity to the SSTR2, SSTR5 and to a lesser degree SSTR3.  SSTR2 is 
predominantly expressed and known to be related to a clinical benefit from 
octreotide therapy for the relief of the syndrome symptoms. SSTR3 and 
SSTR5 have known apoptotic and cytostatic roles. Octreotide may interact 
with the receptors to directly mediate the trigger that produces an inhibition 
of cell division and, indirectly, by the suppression of growth factors and 
hormones that stimulate tumor growth.  Research Question: Primary – Is 
there a difference in the predictive value of chromogranin A levels for tumor 
progression among patients treated with octreotide compared to those not 
treated? Secondary – Does octreotide alter time to progression of disease? 
Methods: For the purpose of this abstract, retrospective data on a random 
30% sample (n=76) patient population at H. Lee Moffitt Cancer Center were 
evaluated from the time of diagnosis to progression. Medical records, 
pathology slides, clinical data, laboratory results, and radiographic imaging 
were used for this descriptive study. Results: Changes in CgA level were 
evaluated using logistic regression while controlling for other known and 
suspected prognostic variables. The differences between the treatment groups 
OR=2.2 (.619, 7.979) and the Chi Square test was not significant. Although, 
68% had at least a 2 fold increase, the OR was not significant for difference 
between the groups OR=1.806 (.512, 6.363). Using Cox proportional hazard 
ratio for survival difference, the duration of disease stability, while 
controlling for debulking surgery, hepatic artery embolization, chemotherapy, 
tumor grade, symptoms, and metastatic disease, between the two treatment 
groups was not statistically different (p = 0.2227 >0.05). Conclusions: There 
was not an overall survival difference demonstrated based on octreotide 
therapy; this may be due to the difference of disease severity at time of 
diagnosis and the impact of the secreted hormones responsible for the 
syndrome among the octreotide group. The major weakness of this study was 
the inconsistency of historical data, and sample size. A randomized clinical 
trial is needed to further evaluate benefit related to octreotide therapy.  
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Antibody-directed enzyme prodrug therapy (ADEPT) is based on the 
selective generation of cytotoxic drugs within tumours due to administration 
of an antibody-enzyme conjugate prior to the prodrug. Previous work using a 
chemically conjugated antibody-enzyme fusion protein (Napier et al, 2000) 
showed that immunogenicity hampers repeated administration. A new 
clinical trial uses MFE-CP, a recombinant fusion protein of an anti-CEA scFv 
antibody (MFE-23) and an enzyme (carboxypeptidase G2, CPG2). Since 
MFE-CP is a recombinant molecule there is potential to mutate immunogenic 
sites. A clinically relevant discontinuous conformational epitope on CPG2 
has been identified and mutation of a single amino acid led to a variant with 
reduced immunogenicity (Spencer et al, 2002). Here we report the 
development of a new variant (dmMFE-CP) with a second mutation in the 
CPG2 discontinuous epitope and potential for greater reduction in 
immunoreactivity.  
DmMFE-CP was expressed in Eschichia coli, purified by affinity and size 
exclusion chromatography with a final yield of 100ug/l supernatant. Purity 
was confirmed by SDS-PAGE and western blotting. Binding to CEA was 
confirmed by ELISA. Crucially dmMFE-CP retained intact catalytic activity, 
i.e. 210U/mg despite 2 amino acid changes. DmMFE-CP was then cloned 
into pPICZ B for expression in Pichia pastoris, the host for the currently 
used clinical product. A hexahistidine-tag for purification on immobilized 
metal affinity chromatography and an additional XbaI site were also inserted. 
EcoRI and SalI restriction enzyme digestion of dmMFE-CP was carried out 
prior to amplification by polymerase chain reaction and TOPO TA 
subcloning, which allowed blue-white screening to determine the correct 
insert. The insert was religated into the original vector puc119, digested with 
XbaI and SfiI and ligated into pPICZ B. The construct was transfected into P. 
pastoris, cultured in glycerol containing medium prior to induction with 1% 
methanol. Harvesting at 24 hours and a culture temperature of 25
oC was 
found to give the highest yield of intact fusion protein, i.e. approximately 
10mg/l. DmMFE-CP will now be tested for its immunogenic potential in 
comparison with the currently used clinical product MFE-CP.  
Napier MP, Sharma SK, Springer CJ et al, 2000, Clin Cancer Res, 6, 765. 
Spencer DIR, Robson L, Purdy D et al, Proteomics, in press  
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The synthesis of new oxygenated and hydroxylated heterocycles has been an 
ongoing area of involvement in our laboratories due to our interest in novel 
phenolic oxidation products
1. These products include 4-heteroaryl-4-
hydroxycyclohexa-2,5-dien-1-ones, otherwise known as heteroaromatic 
quinols, a new class of antitumour agent found to possess highly unusual 
patterns of in vitro activity. Antitumour activity is concentrated in certain 
colon and renal tumour cell lines at the LC50 level (NCI sixty cell line human 
tumour screen). For example, in HCT116 and HT29 colon cell lines, 4-
(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one (NSC 706704, a 
benzothiazole quinol) exhibits LC50 values of 0.47 M and 0.65 M 
respectively (two day assay). In vivo activity against human RXF 944XL 
renal xenografts in nude NMRI mice has also been observed (complies with 
UKCCR guidelines). 
Two major synthetic approaches to this new series of agents have been 
developed. The first approach to benzothiazole quinols involves phenolic 
oxidation of 2-(4-hydroxyphenyl)benzothiazoles using hypervalent iodine 
oxidants. A more versatile approach, however, to a range of heteroaromatic 
quinols involves lithiation of the appropriate heteroaromatic building block 
followed by addition of the resulting nucleophile (e.g. 2-lithiobenzothiazole) 
to protected benzoquinone ketal. Ketal deprotection then gives the required 
heteroaromatic quinol in one-pot in good yields. This methodology has 
provided efficient access to a wide range of substituted quinols, e.g. 
benzothiazole, benzoxazole, benzothiophene, benzofuran, thiazole, thiophene 
and quinoline. 
We have adopted an information-intensive approach towards the elucidation 
of possible mechanistic targets for this series based on COMPARE analyses 
within the NCI database (GI50 panel). For active compounds within this series 
Pearson Correlation Coefficients (PCCs) were found to be > 0.7, indicating a 
conserved mechanism of action. However, the activity profile of compound 
did not correlate well with standard clinical agents in the database 
(http://dtp.nci.nih.gov). Further COMPARE analysis of NSC 706704 
revealed a number of compounds in the database for which the PCC was > 
0.7 including a naturally occurring flavones-derived quinol
2. Target 
COMPARE analysis uncovered the redo-sensitive protein thioredoxin as a 
potential target. This has been validated by experimental observations (low 
M IC50 values vs. thioredoxin). Based on the flavone compound correlation 
and our synthetic interest in isoflavonoids, we have initiated a program 
towards the synthesis of new isoflavone-derived quinols, the results of which 
will also be reported.    
Supported by Cancer Research UK and the University of Nottingham 
1 Wells G, Bradshaw TD, Diana P, Seaton A, Shi DF, Westwell AD, Stevens 
MFG, (2000) Bioorg. Med. Chem. Lett. 10: 513 
2 Wada H, Fujita H, Murakami T, Saiki Y, Chen CM, (1987) Chem. Pharm. 
Bull. 35: 4757 
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DMU-212: A NOVEL CYP1B1 ACTIVATED ANTICANCER 
PRODRUG 
G.A. Potter, P.C. Butler*, K.C. Ruparelia, T. Ijaz, N.E. Wilsher, E. Wanogho, 
H.L. Tan, T.T.V. Hoang, L.A. Stanley, and M.D. Burke, Cancer Drug 
Discovery Group, School of Pharmacy,  De Montfort University, Leicester 
LE1 9BH. 
 
The cytochrome P450 isoform CYP1B1 has been shown to be expressed in a 
high proportion of human tumours
1, but not in the corresponding normal 
tissues, making this enzyme an attractive target for cancer therapy. We have 
designed the novel antimitotic prodrug DMU-212 using the pharmacophore 
of estradiol
2, the only known endogenous substrate for CYP1B1. DMU-212 
has been shown to be essentially non-toxic to MCF-7 breast cancer cells or 
normal human breast cells (either primary cultures or MCF-10A) which lack 
CYP1B1, but has been shown to be highly cytotoxic to breast tumour cells 
expressing CYP1B1 (MDA-468 or TCDD induced MCF-7), with an in vitro 
therapeutic window of several thousand fold using a 96 hour drug exposure 
time. A very high tumour selectivity has been observed for DMU-212, and in 
the test systems used here we have obtained a tumour selectivity ratio of 
9,000-fold. The cytotoxic effects on cells expressing CYP1B1 could be seen 
after a drug exposure time of only 15 minutes. Toxicity to the expressing 
cells could be reversed to that observed in non-expressing cells using the 
CYP1 family inhibitors acacetin or -naphthoflavone, confirming the 
mechanism of bioactivation. These results suggest that DMU-212 is a non-
toxic and tumour selective anticancer agent with therapeutic potential for the 
treatment of CYP1B1 expressing tumours, and tumours that are resistant to 
conventional chemotherapy. 
1Murray, G.I., Taylor, M.C., McFadyen, M.C.E., McKay, J.A., Greenlee, 
W.F., Burke, M.D. & Melvin, W.T. (1997) Cancer Res., 57, 3026-3031. 
2Potter, G.A., Patterson, L.H. & Burke, M.D. (2001). Aromatic hydroxylation 
activated (AHA) prodrugs. US Patent 6,214,886. 
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A NOVEL SUBCLASS OF THALIDOMIDE ANALOGUE WITH 
ANTI-SOLID TUMOUR ACTIVITY IN WHICH CASPASE 
DEPENDENT APOPTOSIS IS ASSOCIATED WITH ALTERED 
EXPRESSION OF BCL-2 FAMILY PROTEINS 
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Thalidomide is clinically useful in a number of cancers. Anti-tumour activity 
may be related to a number of known properties, including anti-tumour 
necrosis factor (TNF)-, T cell co-stimulatory and anti-angiogenic activities. 
However, it may also involve direct anti-tumour effects. A series of second 
generation thalidomide analogues have been separated into two distinct 
groups of compounds each with enhanced therapeutic potential, i.e.; 
SelCIDs, which are phosphodiesterase (PDE) type IV inhibitors, and 
IMiDs which have unknown mechanism(s) of action. We report here our 
efforts to determine direct anti-tumour effects of thalidomide and compounds 
from both groups. We found that one of the SelCID analogues (SelCID-3) 
was consistently effective at inhibiting tumour growth and viability in a 
variety of solid tumour lines. The anti-tumour activity was independent of 
known PDE4 inhibitory activity and did not involve cAMP elevation. Growth 
arrest was preceded by the early induction of G2/M cell cycle arrest, which 
led to caspase 3 mediated apoptosis. Apoptosis was associated with increased 
expression of pro-apoptotic proteins and decreased expression of anti-
apoptotic bcl-2. Furthermore, extensive apoptosis in vivo was detected during 
SelCID-3 mediated inhibition of tumour growth in a murine 
xenotransplantation cancer model. Our results suggest that this analogue 
represents a novel class of compound with distinct anti-cancer potential. 
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THE IN VIVO DISTRIBUTION OF A CEA DIRECTED ANTIBODY 
CONJUGATED TO THYMIDINE PHOSPHORYLASE,  
C.L. Graham*, H.D. Thomas, G.A. Taylor, D.R. Newell, R. Melton#, A.V. 
Boddy.  
*NICR, Framlington Place, Newcastle University, Newcastle upon Tyne, 
NE2 4HH. #Enact Pharma Plc, Building 115, Porton Down Science Park, 
Salisbury, SP4 0JQ. 
 
Raltitrexed (RTX) is a classical thymidylate synthase (TS) inhibitor used to 
treat colorectal cancer. Inhibition of TS by RTX leads to depletion of dTTP. 
Tumours may overcome TS inhibition through thymidine (TdR) salvage by 
conversion of endogenous TdR to thymidylate using thymidine kinase. To 
block TdR salvage extracellular TdR can be depleted by thymidine 
phosphorylase (TP). The carcinoembryonic antigen (CEA) is expressed at 
low levels on adult colon epithelial cells but overexpressed by the majority of 
colon carcinomas. To achieve tumour-specific TdR depletion TP was 
conjugated to the anti-CEA antibody A5B7, and the distribution of the A5B7-
TP conjugate studied in tumour bearing mice. 
Colorectal carcinoma cells (LoVo, which express high levels of CEA) were 
subcutaneously injected into the right flank of nude mice (1 x 
10
7cells/animal). When the tumours had grown to 1cm
3 the antibody-enzyme 
conjugate was administered intravenously at a dose of 1mg/animal 
(equivalent to a TP activity of 20-25 mmoles of thymine formed per minute). 
Twelve, 24, 36, 48 and 72h after injection of the conjugate plasma, tumour, 
liver, kidney, colon, spleen, brain and lung were collected. TP activity was 
determined by HPLC and the protein content by a BCA protein assay. There 
were no changes in TP activity in any of the tissues other than the plasma and 
tumour, at any of the time points studied as compared with controls. TP 
activity expressed as the rate of thymine formation per g protein in plasma 
and tumour are given in the table 
 
Hour post 
admin 
0 12  24  36  48  72 
Plasma 0,0  33.3  7.4  7.6  1.2,  1.8  0.4 
Tumour  2.3, 2.0  6.6  8.4  5.5  3.3, 2.3  2.8 
Significance 
p< 
0.06, 
0.01 
0.008 ns  0.02  ns,  ns  0.001 
 
These results show that the conjugate does accumulate in the tumour but not 
in any other tissues. However, high levels in the plasma may result in 
systemic toxicity when RTX is administered. Further experiments will 
investigate methods to optimise conjugate delivery to the tumour and to 
reduce levels in plasma in order to define a time-window for the 
administration of RTX.  
This work is funded by a Cancer Research UK, William Ross Studentship. 
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PEPTIDE NANOTECHNOLOGY: APPLICATIONS IN TARGET 
VALIDATION AND DRUG DISCOVERY 
Rob Woodman and Paul Ko Ferrigno* 
MRC Cancer Cell Unit, Hutchison/MRC Research Center, Hills Rd, 
Cambridge CB22XZ 
 
Our goal is first to streamline the validation of cancer drug targets and then to 
apply the information gained to the identification of small molecule drugs. To 
these ends, we are constructing molecular toolkits that we use to study 
cellular proteins in their natural environment and in vitro.   
We screen a library of 10
9 constrained peptides expressed in eukaryotic cells 
for those that bind to the protein under investigation. Typically, a screen of 3 
million peptides yields 30-100 hits that bind to the target protein with 
affinities between 1 and 300 nM. Peptide sequences are used for in silico 
screening of databases for homologous sequences that may provide insights 
into protein partners. Constrained peptides are expressed in cells with the 
goal of disrupting protein-protein interactions. Any phenotype produced in 
this way provides clues about functions of the target protein. We also use the 
peptide sequence to replace the substrate recognition domain of enzymes, 
creating artificial enzymes whose sole substrate is the protein of interest. We 
can thereby direct post-translational modifications such as ubiquitination of 
the target protein. Using such a designer enzyme, we can drive the proteolytic 
degradation of a target protein in human cells. Our next goal is to make 
protein knockouts in human cells. We also make functional protein knockouts 
by using the cell’s own sorting machinery to remove the target protein from 
its compartment, preventing interactions with its normal partners. In 
biochemical studies, GST-fusions to constrained peptides can be used to 
purify the target protein from human cells, yielding information about the 
protein’s in vivo interactions. These GST fusions can also be used to probe 
Western blots of whole cell lysates. GFP fusions to constrained peptides may 
also be used as molecular tracers to monitor the intracellular dynamics of the 
target protein in living cells. Finally, in the first case where we have a 
constrained peptide binding to a clinically important surface of a target 
protein, we have initiated a screen for small molecule drugs that bind to this 
surface. If successful, we will have moved from theoretical drug target to 
lead compound with nanomolar affinity in less than a year.    
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COMPARISON OF STRATEGIES TO OVERCOME THE 
HYPERTENSIVE EFFECT OF COMBRETASTATIN-A-4 
PHOSPHATE IN A RAT MODEL   
DJ Honess
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1, DJ Chaplin
2 and GM Tozer
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1Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon 
Hospital, Northwood, Middx, HA6 2JR, UK and 
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Background and Aim. Combretastatin–A-4 phosphate (CA-4-P) is the lead 
drug of a group of tubulin depolymerising agents currently in clinical trial as 
vascular targeting agents. CA-4-P destabilises endothelial cell microtubules 
and in preclinical models selectively inhibits tumour blood flow (TBF) with 
subsequent induction of tumour necrosis. However CA-4-P causes transient 
hypertension prior to the time of maximum inhibition of TBF (Tozer et al, 
Cancer Res., 1999, 59, 1626). Clinically, CA-4-P has completed Phase I, with 
confirmation of TBF reduction by magnetic resonance imaging, and is 
progressing to Phase II. Patients treated at the maximum tolerated dose also 
exhibit transient hypertension. If uncontrolled, such hypertensive episodes, 
could possibly trigger secondary cardiovascular side effects. This study was 
designed to assess the feasibility of controlling CA-4-P-induced hypertension 
in rats by means of antihypertensive agents in routine clinical use, the   
vasodilator sodium nitroprusside (NP) or the -blocker propranolol (PP). 
Methods and Results. A tail artery and vein of anaesthetised male BD9 rats 
were cannulated. Mean arterial blood pressure (MABP) was monitored 
directly via the arterial cannula, CA-4-P was given ip and NP, PP or saline 
were given by iv infusion. Mean pre-treatment MABP ± 2SE was 84.1 ± 5.3 
mmHg (n = 8). After 30 mg/kg CA-4-P alone MABP rose to 110.3 ± 15.4 
mmHg by 20 min (n = 4), remained stable until 80 min, then fell to control 
values by 120 min. After 10 mg/kg CA-4-P, MABP rose steadily but more 
slowly to 110.7 ± 11.3 mmHg by 60 min (n = 4), began to fall by 110 min, 
but remained elevated in 2/4 rats at 120 min. Infusion of 20 µg/kg/min NP 
reduced MABP to about 60 mmHg and of 40 µg/kg/min PP to about 70 
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with either NP or PP infused at rates up to 20 or 100 µg/kg/min respectively, 
starting the NP as MABP began to rise, and adjusting infusion rate in 
response to individual fluctuations. PP elicits its response more slowly, and it 
proved more effective in maintaining constant MABP to start infusing PP 
before giving CA-4-P. With the infusion of either NP or PP, MABP was 
successfully maintained for 120 min within 5 – 10 mmHg of the starting 
value. When the infusion ended, MABP rose sharply in all NP-treated rats, 
but in no PP-treated rats. This is most likely due to vasoconstriction on abrupt 
NP withdrawal or, less probably, to slowing of CA-4-P clearance by a 
pharmacokinetic interaction between NP and CA-4-P. Conclusions. The 
hypertensive effect of CA-4-P can be successfully abrogated by concomitant 
infusion with conventional, clinically applicable antihypertensive agents with 
differing modes of action. This may reduce or eliminate possible 
cardiovascular side effects of this type of antivascular drug. Prevention of 
hypertension may also enhance the reduction in specific tumour blood flow, 
and further animal studies are in progress to investigate this. 
This work was supported by a grant from Oxigene Inc. and Cancer Research 
UK 
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SRC TYROSINE KINASE-DEPENDENT CELLULAR ADHESION 
CHANGES IN A MODEL OF COLON CANCER METASTASIS 
VG Brunton*, RJ Jones, AW Wyke, E Avizienyte & MC Frame 
Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback 
Road, Bearsden, Glasgow, G61 1BD, UK 
 
One of the key steps leading to the development of metastatic disease is 
altered cell adhesions, which contribute to cell release from primary sites and 
establishment of cells at ectopic sites.  A common feature of metastatic 
progression in colon cancer is elevated expression and/or activity of Src 
tyrosine kinase, although the mechanism of action is unclear.  In the Fidler 
model of human colon cancer metastasis, Src expression and activity is 
increased in cells that exhibit metastatic potential.  In this model, colon 
cancer cells (KM12C) derived from a primary tumour, metastasise 
infrequently to the liver when injected into the spleens of mice.  However, 
when cells from these infrequent metastases were subjected to several rounds 
of injection/metastasis, a highly metastatic variant was derived (KM12L4A).  
Expression of constitutively active c-Src in the non-metastatic KM12C cells 
resulted in a dramatic change in morphology.  The parental KM12C cells 
grow as tight clusters with strong cell-cell junctions, while the same cells 
expressing activated Src have weakened cell-cell contacts and form 
prominent cellular protrusions which can be reversed by a blocking antibody 
to v integrin.  Integrin engagement in the non-metastatic cells results in the 
formation of very small, non-protrusive focal complexes, while the metastatic 
KM12L4A cells and the non-metastatic cells expressing active Src have 
robust focal adhesions.  The formation of these adhesions is delayed in the 
metastatic cells by expression of kinase defective Src mutants indicating that 
the Src kinase activity is required.  However, under normal growth conditions 
the KM12L4A cells expressing kinase defective Src mutants also form 
prominent cellular protrusions similar to those found in the cells expressing 
constitutively active Src.  Thus the kinase activity is not required for the 
maintenance of these integrin-dependent adhesions and may require the 
adaptor function of Src mediated by its SH2 and SH3 domains.  Using time-
lapse video microscopy we found that the protrusions formed in cells 
expressing active Src were highly motile structures whereas those formed in 
cells expressing the kinase defective Src protein were static.  Thus the kinase 
activity is required for the dynamic regulation of these integrin-dependent 
adhesions.  Furthermore Src kinase activity is required for the disassembly of 
cell-cell adhesions as expression of kinase defective Src in the metastatic 
cells impairs their ability to breakdown cell-cell adhesions in low calcium 
conditions.  Src is found at both cell-matrix and cell-cell adhesions in these 
colon epithelial cells and it appears that both the kinase activity and adaptor 
function of Src may play a role in the regulation of these adhesions and that 
inhibitors of both may be useful therapeutics in the treatment of metastatic 
disease. 
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FUNCTIONAL CHARACTERISATION OF DIFFERENTIALLY 
EXPRESSED GENE TRANSCRIPTS ASSOCIATED WITH COLON 
CANCER METASTASIS 
E. Foran*, P. McWilliam, D.T. Croke, A.C. Long, Dept. of Biochemistry, 
Royal College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2. 
 
Metastasis is the process by which malignant cells leave their primary site 
and spread to distant locations in the body.  Identification of genes that are 
differentially expressed between primary and secondary tumours is 
fundamental to the understanding of the metastatic phenotype.  Previously we 
have used two gene expression profiling techniques for this purpose - 
Suppression Subtraction Hybridization (SSH) and Serial Analysis of Gene 
Expression (SAGE).  These techniques were applied to the isogenic cell lines 
SW480, a primary tumour, and SW620, a lymph node metastasis from the 
same patient.  
SSH analysis implicated, among other genes, the actin-binding protein L-
plastin and several proteasomal subunits in cancer progression.  Regulatory 
and catalytic subunits of the proteasome were down regulated in SW620, the 
metastatic cell line, with respect to SW480.  Following on the initial data 
obtained using SSH, we tested whether partial inhibition of the proteasome in 
SW480 had any effect on cell motility and morphology.  Basal levels of 
motility and proliferation were first ascertained, and SW480 was found to be 
less migratory than SW620.  MTS assays showed SW620 to be proliferate at 
a significantly greater rate than SW480.  Treatment of the SW480 cells with 
the proteasomal inhibitor lactacystin resulted in increased migration of cells, 
as illustrated by a colloidal gold assay. 
Expression of L-plastin at the protein level was significantly greater in the 
metastatic SW620 cells when compared to SW480.  Protein level differences 
were much greater than RT-PCR analysis of mRNA levels had indicated.  
The SW480 cell line was stably transfected with L-plastin and functional 
analysis was carried out.  Overexpression of L-plastin increased the 
proliferation of these cells.  Treatment of L-plastin transfected cells with 
lactacystin resulted in increased expression of L-plastin at the protein level, 
indicating that L-plastin turnover may be regulated by the proteasome. 
These results suggest that differential expression of proteasomal subunits and 
L-plastin are potentially key regulators of migration and proliferation in these 
cells and thus markers for tumour progression in a cell line model for colon 
cancer metastasis. 
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REFINEMENT OF THE TYLOSIS OESOPHAGEAL CANCER (TOC) 
MINIMAL REGION TO 65KB BY HAPLOTYPE ANALYSIS USING 
NOVEL MICROSATELITE MARKERS AND SNPS 
Langan JE*
1, Risk JM
1, Field JK
1, 2 
1. Molecular Genetics and Oncology Group, Department of Clinical Dental 
Sciences, University of Liverpool, Liverpool L69 3GN, UK. 
2. Roy Castle International Centre for Lung Cancer Research. 
 
Tylosis is a benign autosomal dominantly inherited disorder of the skin that 
manifests as focal thickening of the palmar and plantar surfaces.  Tylosis is 
associated with familial oesophageal cancer in two large families in the UK 
and USA and a smaller German pedigree.  The familial cancer association is 
rare in the general population, but the gene is also thought to be involved in 
the development of sporadic squamous cell oesophageal cancer.  We have 
previously mapped the Tylosis with Oesophageal Cancer (TOC) gene locus 
to chromosome 17q25 between markers D17S785 and D17S722, spanning a 
region of 500kb. This region is covered entirely by 4 RPCI-11 BAC clones 
that are more than 95% sequenced and have been assembled into a contig.  
The region contains at least 17 candidate genes that were predicted using 
bioinformatics programs. 
In an attempt to further refine the region we have aligned SNPs to the contig 
and looked for novel microsatellite markers that could be used in haplotype 
analysis.  Over 600 SNPs on the NCBI SNP database aligned with the region 
(although some proved to be the same SNP) and overlapping sequence data 
indicated several additional SNPs.  Analysis of the sequence data revealed a 
possible 20 novel microsatellites that ranged from di- to penta-nucleotide 
repeats. Initial haplotype studies on members of the UK and US pedigrees 
showed that 9 of the repeats were polymorphic in these families.  These novel 
markers have been submitted to GenBank and have been assigned D numbers 
by GDB.   
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by polyacrylamide gel electrophoresis before haplotype analysis in the UK 
and US families.  Two of the new markers, D17S2239 and D17S2244, 
redefined the TOC minimal region and have narrowed the critical region 
from ~500kb to just over 65kb.  This has not only removed 13 candidate 
genes from the study but has also eliminated 3 RPCI-11 BAC clones from the 
minimal contig.   
Haplotype analysis of the 25 SNPs on the NCBI database that remain within 
the TOC minimal region, together with the 20 possible SNPs in this region, is 
being carried out via a relatively new method called “confronting two pair 
primers” which will be described.  These SNP data will assist in the 
refinement of the TOC minimal region and may identify disease-specific 
SNPs in candidate genes. 
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THE 6 INTEGRIN SUBUNIT C-TERMINAL 11 AMINO ACIDS ARE 
SUFFICIENT TO PROMOTE INVASION BY SQUAMOUS CELL 
CARCINOMA (SCC) CELLS 
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The v6 integrin heterodimer is expressed de novo during wound healing 
and in various epithelial neoplasia.  In oral SCC cells, over-expression of 
v6  in vitro, enhances cellular invasion through a ligand-dependent 
upregulation of secreted pro-MMP-9.  We reported previously that the unique 
C-terminal 11 amino acids of the 6 integrin subunit are critical for v6-
dependent MMP-9 upregulation and, as such, are essential for v6-mediated 
invasion.  We investigated whether the C-terminal 11 amino acids of 6 were 
not only essential for v6-mediated invasion but also sufficient to induce an 
enhanced invasive phenotype.  To address this we used retroviral 
transduction of cDNAs to generate SCC cell lines over-expressing either wild 
type 3 or a 3 chimaeric mutant which has its cytoplasmic domain extended 
by the addition of the C-terminal 11 amino acids of 6.  The generated cell 
lines were V3B3 and V3B311aa (wild type and chimaeric 3 infectants, 
respectively), and the null transfectant cell line, C1.  Flow cytometry 
confirmed that the V3B3 and V3B311aa cells expressed cell surface v3 
to the same degree, whereas C1 cells had no v3.  Adhesion assays, on 
vitronectin, showed similar levels of adhesion by the V3B3 and V3B311aa 
cell lines (38.60% and 39.45% respectively) which was enhanced relative to 
C1 null transfectant cells (6.52%).  Adhesion of V3B3 and V3B311aa cells 
to vitronectin was inhibited by LM609 (anti-v3 blocking antibody) by 
30.62% and 26.01%, respectively, but did not affect C1 cell adhesion 
(6.66%).  Interestingly, combined antibody blockade of both v and 1 
reduced V3B3 and V3B311aa adhesion further (50.29% + 67.7% inhibition 
respectively).  Haptotactic migration assays, towards vitronectin, showed that 
the V3B3 and V3B311aa cells attained similar levels of substrate specific 
haptotaxis (20.29% and 21.79%), whereas C1 cells displayed only basal 
levels of migration (2.01%).  V3B3 and V3B311aa migration was reduced 
to basal levels in the presence of LM609 (3.92% and 0%).  These data 
indicated that the wild type and mutant v3 heterodimers, in V3B3 and 
V3B311aa cells, are functional as vitronectin receptors.  Invasion, through 
Matrigel, of V3B311aa cells (131.17%) was significantly higher than that of 
the V3B3 cell line (100%) (p=0.011).  Surprisingly, gelatin zymography 
demonstrated no significant difference in MMP-9 expression, between V3B3 
and V3B311aa (p=0.164), but the V3B311aa cells secreted substantial 
quantities of pro-MMP-2, whereas, the V3B3 cells did not produce a 
detectable amount.  Therefore, the C-terminal 11 amino acids of the 6 
integrin subunit, depending on their heterodimer context, are sufficient to 
enhance SCC cell invasion by promoting either gelatinase A (MMP-9) or B 
(MMP-2) production. 
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NOVEL CROSS TALK BETWEEN MEK AND S6K2 IN FGF-2 
INDUCED PROLIFERATION OF SCLC CELLS 
Pardo O.E., Arcaro A., Seckl M.J., Lung Cancer Biology Group, Division of 
Medicine, Hammersmith Campus of Imperial College School of Medicine, 
London W12 ONN, UK. 
  
Here, we show that fibroblast growth factor-2 (FGF-2) induces proliferation 
of H510 and H69 small cell lung cancer (SCLC) cells. However, selective 
activation of the mitogen-activated protein kinase kinase (MEK) pathway 
was seen in H510, but not H69 cells. Moreover, inhibition of MEK with 
PD098059 blocked FGF-2-induced proliferation in H510 cells only. 
Similarly, ribosomal protein S6 kinase 2 (S6K2), a recently identified 
homologue of S6K1 was activated by FGF-2 in H510, but not H69 cells. This 
correlated with increased sensitivity of H510 cells to FGF-2 as compared to 
H69 cells. S6K2 activation was independent of phosphatidylinositol-3 kinase, 
but was sensitive to inhibition of the MEK pathway. These data suggest that 
S6K2 is a novel downstream target of MEK. In contrast to S6K2, S6K1 was 
activated in both SCLC cell lines. Inhibition of the mammalian target of 
rapamycin with 10 ng/ml rapamycin blocked S6K1 activation and 
proliferation of both lines. However, even at 100 ng/ml, rapamycin only 
partially inhibited S6K2. Strikingly, this correlated with inhibition of MEK 
signalling. Our data indicate that S6K1, and possibly S6K2, are involved in 
FGF-2-induced SCLC cell growth, a notion supported by the overexpression 
and higher baseline activity of both isoforms in SCLC lines, as compared to 
normal human type-II pneumocytes. 
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INTERLEUKIN-12 POLYMORPHISMS AND GASTRO-
OESOPHAGEAL CANCER 
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AIM: The host immunological response to insult depends upon a balance 
between anti-inflammatory cytokines (e.g.interleukin-10) and pro-
inflammatory cytokines such as interleukin-12. A previous study by this 
group demonstrated that the IL-10R2 allele is over-represented in H. pylori 
negative gastric cancer. 
We therefore decided to test whether there were any associations of IL-12 
with gastro-oesophageal cancer. 
METHODS: DNA was prepared from 135 patients with gastric or 
oesophageal cancers and 95 normal controls. The samples were genotyped 
using allele-specific primer polymerase chain reaction, and the results were 
then analysed with respect to tumour type and H. pylori status. 
RESULTS: There were no differences in allele frequencies between the 
cancer and the control groups (80% allele A, 20% allele C). The genotype 
frequencies were also similar between the two groups (p=0.9) and were not 
influenced by histological tumour type. However, in the H. pylori-positive 
group 71.1% of patients were genotype A/A and 26.7% were A/C compared 
to 51.4% A/A and 42.9% A/C in the H. pylori-negative group (p=0.07). 
CONCLUSIONS: Our results suggest that there is no significant relationship 
between this IL-12 marker and histological tumour type. However the trend 
to significance at this locus implicates a probable role for the IL-12 p40 C 
allele in H. pylori negative gastro-oesophageal cancer. 
 
 
 
 
P285 
PYRIMIDINE METABOLISM AND G1/S TRANSITION IN COLON 
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Availability of cellular pyrimidine nucleotides is critical for DNA synthesis 
and the cellular response to perturbations in pyrimidine nucleotide pools is 
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pyrimidine metabolic enzymes and G1/S transition proteins, and the role of 
these G1/S pathways in colon cancer prognosis, was investigated.   
Immunohistochemical analysis of colon tumour cells demonstrated p21
WAF1 
protein expression correlated with TP protein expression (p=0.005).   
Cytoplasmic dUTPase (p=0.05) or p27
KIP1 (p=0.031) protein expression was 
directly correlated with DPD.  Cytoplasmic dUTPase (p=0.05), cyclin D1 
(p=0.01), p53 (p=0.02) or p21
WAF1 (p=0.001) protein expression was 
associated with nuclear dUTPase protein expression.   
Nuclear dUTPase protein was an independent predictor of survival in Dukes' 
C colon cancer, where patients expressing this isoform had a poorer survival 
than those negative for nuclear dUTPase (Odds ratio 4.1; 95 % CI 1.3-12.3; 
p=0.01).  Multivariate analysis of combined enzyme expression demonstrated 
Dukes' C colon cancer patients with positive expression of both nuclear 
dUTPase and TP protein in their tumour cells have a highly increased risk of 
death compared to patients with positive expression of only one or none of 
these enzymes (Odds ratio=13.2, 95% CI=3.2-54.3, p<0.001).  Patients 
(Dukes' A, B, C and D) with colon tumour cells positively expressing nuclear 
dUTPase in combination with either p53 (Odds ratio 4.7, 95% CI 1.5-14.4, 
p=0.007) or p21 (Odds ratio 2.9, 95% CI 1.2-6.8, p=0.017) have poorer 
survival than those expressing one or none of these proteins. 
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